脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较*

doi:10.3969/j.issn.1672-5069.2022.05.020

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (5): 685-688.doi: 10.3969/j.issn.1672-5069.2022.05.020

脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较^*

李婷, 毛小荣, 张雪梅, 李俊峰

710004 西安市西安交通大学第二附属医院感染病科(李婷);兰州大学第一医院感染病科(毛小荣,张雪梅,李俊峰)

收稿日期:2022-01-28 出版日期:2022-09-10 发布日期:2022-09-22
通讯作者: 李俊峰,E-mail:junfenglee@126.com
作者简介:李婷,女,27岁,医学硕士,医师。主要从事肝硬化诊治研究。E-mail:18719797318@163.com
基金资助:
国家自然科学基金资助项目(编号:81800528);甘肃省自然科学基金资助项目(编号:20JR5RA364);甘肃省重点研发计划项目(编号:20YF2FA011);甘肃省感染肝病临床医学研究中心研究项目(编号:21JR7RA392);兰州大学第一医院院长基金资助项目(编号:ldyyyn2020-02/ldyyyn2020-14)

Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS

Li Ting,Mao Xiaorong, Zhang Xuemei, et al.

Department of Infectious Dseases, Second Affiliated Hospital, Jiaotong University, Xi’an 710004, Shaanxi Province, China

Received:2022-01-28 Online:2022-09-10 Published:2022-09-22

摘要/Abstract

摘要： 目的比较脾切除术与经颈静脉肝内门腔静脉内支架分流术(TIPS)治疗肝硬化患者门静脉血栓(PVT)发生率的差异。方法 2017年1月～2018年12月兰州大学第一医院诊治的肝硬化并发脾功能亢进症患者96例,其中接受脾切除者45例,接受TIPS术治疗者51例。术后随访12个月,使用腹部超声或CT或CTA检查诊断PVT。应用Kaplan-Meier法计算PVT累计发生率。结果在术后1个月、3个月、6个月和12个月,脾切除术组PVT累计发生率分别为40.0%、46.7%、48.9%和48.9%,显著高于TIPS术组(分别为7.8%、9.8%、15.7%和21.6%,P<0.05);在接受脾切除术患者,基线指标比较发现PVT组门静脉主干直径显著大于非PVT组,差异具有统计学意义(P<0.05);在TIPS术后1年,发生PVT患者11例(21.6%)。基线指标比较,未发现发生与未发生PVT组各指标具有统计学差异(P>0.05)。结论在肝硬化并发脾功能亢进症患者,接受脾切除术后PVT累计发生率显著高于TIPS术。因此,术前应认真评估病情,严格掌握适应证,择优选择手术方法,并积极给予防治处理。

关键词: 肝硬化, 脾切除术, 经颈静脉肝内门腔静脉内支架分流术, 门静脉血栓

Abstract: Objective The purpose of this study was to compare the incidence of portal vein thrombosis (PVT) after splenectomy or transjugular portal systemic shunt(TIPS)in patients with cirrhosis and hypersplenism. Methods 96 patients with cirrhosis and hypersplenism were enrolled and underwent splenectomy (n=45) or TIPS (n=51) in the Second Hospital, Lanzhou University, between January 2017 and December 2018, and all the patients were followed-up for one years. The PVT was diagnosed on ultrasonography, CT or CTA. The cumulative incidences between the two groups were compared by Kaplan-Meier method. Results At 1 month, 3 months, 6 months and 12 months after operation, the cumulative incidences of PVT in patients receiving splenectomy were 40.0%, 46.7%, 48.9% and 48.9%, significantly higher than 7.8%, 9.8%, 15.7% and 21.6% (P<0.05) in patients underwent TIPS; in patients receiving splenectomy, the baseline material analysis showed that the diameter of portal vain in 22 patients with PVT was significantly wider than in 23 patients without(P<0.05); one-year after TIPS, the incidence of PVT was 21.6%, and there were no significant differences as respect to baseline materials between patients with and those without PVT(P>0.05). Conclusion The cumulative incidence of PVT in patients with cirrhosis after splenectomy is relatively higher than that after TIPS. Therefore, the clinicians should carefully evaluate patient's condition before operation, strictly meeting the indications of splenectomy or TIPS, and make the appropriate choice in this setting.

Key words: Liver cirrhosis, Hypersplenism, Splenectomy, Transjugular portal systemic shunt, Portal vein thrombosis

李婷, 毛小荣, 张雪梅, 李俊峰. 脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 685-688.

Li Ting,Mao Xiaorong, Zhang Xuemei, et al.. Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS[J]. Journal of Practical Hepatology, 2022, 25(5): 685-688.

参考文献

[1]Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: A population-based study. J Clin Gastroenterol, 2015, 49(8): 690-696.
[2]Yamada S, Morine Y, Imura S, et al. Liver regeneration after splenectomy in patients with liver cirrhosis. Hepatol Res, 2016, 46(5): 443-449.
[3]Dong F, Luo SH, Zheng LJ, et al. Incidence of portal vein thrombosis after splenectomy and its influence on transjugular intrahepatic portosystemic shunt stent patency. World J Clin Cases, 2019, 7(17): 2450-2462.
[4]Ushitora Y, Tashiro H, Takahashi S, et al. Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement of liver function. Dig Surg, 2011, 28(1): 9-14.
[5]Boike JR, Flamm SL. Transjugular intrahepatic portosystemic shunts: advances and new uses in patients with chronic liver disease. Clin Liver Dis, 2020, 24(3): 373-388.
[6]Valentin N, Korrapati P, Constantino J, et al. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2018, 30(10): 1187-1193.
[7]Yue-Meng W, Li YH, Wu HM, et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost, 2018, 24(3): 462-470.
[8]Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med, 2011, 25(2): 169-186.
[9]Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol, 2013, 58(3): 593-608.
[10] Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology, 1985, 89(2): 279-286.
[11] Loring LA, Panicek DM, Karpeh MS. Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: is routine surveillance imaging necessary? J Comput Assist Tomogr, 1998, 22(6): 856-860.
[12] Zhou JB, Luo BY, Liu CW, et al. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization. ANZ J Surg, 2018, 88(10): E725-e729.
[13] Jiang GQ, Bai DS, Chen P, et al. Risk factors for portal vein system thrombosis after laparoscopic splenectomy in cirrhotic patients with hypersplenism. J Laparoendosc Adv Surg Tech A, 2016, 26(6): 419-423.
[14] Huang D, Tao M, Cao L, et al. Risk factors and anticoagulation effects of portal vein system thrombosis after laparoscopic splenectomy in patients with or without cirrhosis. Surg Laparosc Endosc Percutan Tech A, 2019, 29(6): 498-502.
[15] Jiang GQ, Bai DS, Chen P, et al. Predictors of portal vein system thrombosis after laparoscopic splenectomy and azygoportal disconnection: a retrospective cohort study of 75 consecutive patients with 3-months follow-up. Int J Surg, 2016, 30: 143-149.
[16] 韩东, 彭经纬, 谢辉晋. 脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究. 实用肝脏病杂志, 2020, 23(5): 409-412
[17] Modaresi Esfeh J, Ansari-Gilani K. Transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol, 2020, 32(6): 762-763.
[18] Lyu Y, He C, Wang Z, et al. Association of nonmalignant portal vein thrombosis and outcomes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. Radiology, 2017, 285(3): 999-1010.
[19] Zhang L, Huan H, Tong H, et al. Warfarin prevented de novo portal vein thrombosis after transjugular intrahepatic portosystemic shunt: A retrospective study. Medicine (Baltimore), 2020, 99(2): e18737.
[20] Wang JT, Zhao HY, Liu YL. Portal vein thrombosis. Hepatobiliary Pancreat Dis Int, 2005, 4(4): 515-518.

脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较^*

Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	南月敏, 李佳峥. 肝硬化与感染[J]. 实用肝脏病杂志, 2022, 25(5): 609-611.
[2]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[3]	龚豪, 黄丽, 张庆红, 李涛, 史秀岩. 应用尿微量白蛋白、β2-微球蛋白和N-乙酰-β-D氨基葡萄糖苷酶评估失代偿期肝硬化患者肾损伤效能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 681-684.
[4]	杨静, 程艳丽. 特发性非肝硬化性门脉高压1例并文献复习[J]. 实用肝脏病杂志, 2022, 25(5): 750-752.
[5]	中国医药生物技术协会慢病管理分会. 肝硬化合并糖尿病患者血糖管理专家共识[J]. 实用肝脏病杂志, 2022, 25(5): 761-S1.
[6]	季雪纯, 金世柱, Nepal Narayan, 李宁, 杨宁宁, 张思佳, 林秋池, 陈浩源. 高位食管静脉曲张破裂出血患者内镜诊治经验:10年单中心回顾性分析[J]. 实用肝脏病杂志, 2022, 25(4): 530-533.
[7]	赵栩, 李自琼, 欧喻莹, 郭丹. 肝硬化患者医院内感染风险预测列线图模型的构建[J]. 实用肝脏病杂志, 2022, 25(4): 534-537.
[8]	汤磊, 彭蕾, 叶珺, 张振华, 邹桂舟. 影响慢性乙型肝炎患者进展为肝硬化的多因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 538-541.
[9]	李芳, 王衍森, 翁璐昕. 高频超声肝实质纹理特征定量联合血清AFP-L3水平评估乙型肝炎肝硬化患者肝功能分级价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 542-545.
[10]	郑丽雅, 田澄, 李娜. 剪切波弹性成像技术联合多参数评估肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 546-549.
[11]	何薇, 张晓彬, 刘迎娣, 何占娣. 30岁以下人群食管胃静脉曲张患者临床特点分析[J]. 实用肝脏病杂志, 2022, 25(4): 550-553.
[12]	王宝锋, 马彦高, 李义, 曾宪强, 周进学. 增强MRI扫描在乙型肝炎肝硬化背景下对原发性肝癌的诊断价值分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 554-557.
[13]	詹惠珍, 杜雅钦, 王松姣. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 395-398.
[14]	郭慧雯, 张峰, 肖江强, 张玮, 张明, 邹晓平, 诸葛宇征. 球囊导管闭塞下逆行性静脉栓塞术治疗胃静脉曲张破裂出血患者疗效分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 407-410.
[15]	郑小勤, 徐辉, 李丽, 靳华, 汪晓军, 勾春燕. 家族聚集性原发性胆汁性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2022, 25(2): 207-210.